AstraZeneca ( (GB:AZN) ) has shared an update.
AstraZeneca’s Imfinzi, in combination with chemotherapy, has been approved by the European Union for treating resectable non-small cell lung cancer (NSCLC) at high risk of recurrence. This approval is based on the AEGEAN Phase III trial, which demonstrated a 32% reduction in the risk of recurrence, progression, or death compared to neoadjuvant chemotherapy alone. The approval marks a significant step in improving outcomes for NSCLC patients in Europe, offering a new immunotherapy-based regimen that extends the time patients live without cancer recurrence. This development underscores AstraZeneca’s commitment to transforming care in early-stage lung cancer, where there is significant potential for cure.
More about AstraZeneca
AstraZeneca is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of diseases in oncology, cardiovascular, renal, and metabolism, and respiratory and immunology. In the field of oncology, AstraZeneca is committed to advancing treatments for lung cancer, including early-stage detection and innovative therapies.
YTD Price Performance: 8.82%
Average Trading Volume: 2,714,787
Technical Sentiment Signal: Strong Sell
Current Market Cap: £176.2B
See more data about AZN stock on TipRanks’ Stock Analysis page.